Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ctDNA-guided adjuvant treatment intensification in resected stage III/high-risk stage II colon cancer
2021-002169-16Phase 2Active
- Sponsor
- Gruppo Oncologico Nord Ovest
- Start
- Mar 2022
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of oxaliplatin, capecitabine, fluorouracil, levoleucovorin, irinotecan and 1 more in colon cancer (2 arms), sponsored by Gruppo Oncologico Nord Ovest. Started Mar 2022; status: active.
02
Drugs
oxaliplatincapecitabinefluorouracillevoleucovorinirinotecan
03
Conditions
colon cancer
Beyond the preview
Go deeper on 2021-002169-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-002169-16.